secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-08-03T20:47:55+00:00
Accession:  0001213900-26-084687
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics 2026 annual meeting voting results; all proposals approved
------------------------------------------------------------------------------

- Elected Judith Shizuru and Tom Wiggans as Class II directors with ~9.27M and ~9.28M votes for, respectively.
- Ratified PricewaterhouseCoopers as independent auditor for FY2026 with 20.6M votes for (97.7% of votes cast).
- Advisory say-on-pay approved with 9.0M for, 604k against, 73k abstain (excluding 11.4M broker non-votes).
- Quorum of 75% (21.1M of 28.0M shares) represented at the July 31, 2026 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026084687/0001213900-26-084687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026084687/ea0300286-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-084687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer